Sign in
Not yet recruitingPhase 2

A Study to Evaluate the Safety and Efficacy of Multiple Dose of STSP-0902 in Patients With Oligozoospermia and/or Asthenozoospermia.

Key facts

Who runs it
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
72 people, planned
Started
Sept 2026
Expected to end
Sept 2027
Type of study
Interventional, 3 groups
Treatments tested
  • STSP-0902 injection
  • Placebo
Record updated
22 September 2026

Who can take part

Age
18 years to 50 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Male volunteers, aged between 18 and 50 years
  • Referring to the WHO 5th edition manual, the patient is diagnosed with oligozoospermia, asthenozoospermia, or oligo asthenozoospermia, and both routine semen analysis test results during the screening period meet Criterion A and/or Criterion B:; A:1×10⁶/mL<sperm concentration<15×10⁶/mL, or total sperm number < 39×10⁶. B:1% <progressive motility sperm percentage (PR%) <32%; If the test result shows sperm concentration<5×10⁶/mL, Y chromosome microdeletion (AZF gene testing) abnormalities should be ruled out
  • Participants (including their partners) must use effective non pharmacological contraceptive measures and have no plans for conception or sperm donation from the time of signing the informed consent form until one month after the end of the last drug administration
  • Participants shall complete semen collection in accordance with the study protocol, have fully understood the study content, procedures and potential adverse reactions, and voluntarily sign the informed consent form

Who cannot take part

  • Participants who have experienced a fever exceeding 38.5℃ occurred within 1 month before administration
  • Screen for participants who have received treatment affecting spermatogenic function within the previous month or are scheduled to receive such treatment during the trial period
  • Screen for participants with a history of treatment with nerve growth factor-related drugs within the previous month (e.g. Mouse Nerve Growth Factor for Injection)
  • Participants who have undergone any major surgery within 3 months prior to screening or have surgery planned during the trial period
  • Diagnosed with malignant tumor or recently received long term radiotherapy
  • Participants who have taken any investigational product or participated in any clinical trial of drug, devices or vaccines intervention within 3 months prior to screening
  • Oligospermia and/or asthenospermia with identifiable etiologies, such as reproductive system infectious diseases, genital trauma, inguinal or genital surgery, severe varicocele (Grade III), cryptorchidism, genital tract obstruction, genetic factors, related endocrine disorders(e.g, Hypogonadotropic hypogonadism , uncontrolled diabetes mellitus), pituitary diseases, post-radiotherapy and chemotherapy status, exposure to reproductive-toxic drugs, immune factors, etc
  • The presence of diseases without effective control or that may lead to hospitalization during screening may significantly increase the safety risks for trial participants or interfere with the interpretation of study results
  • Participants who are allergic to any NGF or who, in the judgment of the investigator, are at risk of allergy as a result of participation in the study
  • Diagnosed with a mental illness
  • Participants with a positive result for either human immunodeficiency virus antibody (anti-human immunodeficiency virus antibody, HIV-Ab) or treponema pallidum-specific serum antibody (anti-treponema pallidum antibody, TPAb)
  • Screening-phase follicle-stimulating hormone (FSH) result ≥8 IU/L
  • Participants with other factors that are not suitable for participation in this study as judged by the investigator

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of STSP-0902 in Patients with Oligozoospermia and/or Asthenozoospermia.

The 3 groups in the trial

  • low dose of STSP-0902 subcutaneous injection or dose-matched placebo (First cohort)Treatment being tested

    24 subjects will be randomized to receive low dose of STSP-0902 subcutaneous injection or dose-matched placebo (First cohort)

    Treatment: STSP-0902 injection and Placebo

  • middle dose of STSP-0902 subcutaneous injection or dose-matched placebo (Second cohort)Treatment being tested

    24subjects will be randomized to receive middle dose of STSP-0902 subcutaneous injection or dose-matched placebo (Second cohort)

    Treatment: STSP-0902 injection and Placebo

  • high dose of STSP-0902 subcutaneous injection or dose-matched placebo (Third cohort)Treatment being tested

    24 subjects will be randomized to receive high dose of STSP-0902 subcutaneous injection or dose-matched placebo (Third cohort)

    Treatment: STSP-0902 injection and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, and Multiple Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetic, and Immunogenicity of STSP-0902 in Patients With Oligozoospermia and/or Asthenozoospermia
Criteria questions
Built from NCT07833943, who can take part
Record updated
22 September 2026